bluebird bio, Inc., Carlyle, and SK Capital Partners announced on May 5, 2025, that all required regulatory approvals to complete the previously announced acquisition of bluebird bio have been received. This marks a significant milestone in the acquisition process, removing a key hurdle for the transaction.
The receipt of all necessary regulatory clearances paves the way for the finalization of the acquisition, which will see bluebird bio become a privately held company under the ownership of funds managed by Carlyle and SK Capital. This development is crucial for the gene therapy maker, which had faced financial challenges.
This approval allows Carlyle to proceed with its strategic investment in the healthcare sector, particularly in gene therapies for severe genetic diseases. The successful navigation of regulatory processes is essential for Carlyle's large-scale acquisitions and its ability to expand its portfolio in strategic areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.